The Tryptophan Catabolite Picolinic Acid Selectively Induces the Chemokines Macrophage Inflammatory Protein-1α and -1β in Macrophages

Maria Carla Bosco, Annamaria Rapisarda, Stefano Massazza, Giovanni Melillo, Howard Young and Luigi Varesio
J Immunol March 15, 2000, 164 (6) 3283-3291; DOI: https://doi.org/10.4049/jimmunol.164.6.3283

Abstract

We previously found that the tryptophan catabolite picolinic acid (PA) is a costimulus for the activation of macrophage effector functions. In this study, we have investigated the ability of PA to modulate the expression of chemokines in macrophages. We demonstrate that PA is a potent activator of the inflammatory chemokines MIP (macrophage inflammatory protein)-1α and MIP-1β (MIPs) mRNA expression in mouse macrophages in a dose- and time-dependent fashion and through a de novo protein synthesis-dependent process. The induction by PA occurred within 3 h of treatment and reached a peak in 12 h. The stimulatory effects of PA were selective for MIPs because other chemokines, including monocyte chemoattractant protein-1, RANTES, IFN-γ-inducible protein-10, MIP-2, and macrophage-derived chemokine, were not induced under the same experimental conditions and were not an epiphenomenon of macrophage activation because IFN-γ did not affect MIPs expression. Induction of both MIP-1α and MIP-1β by PA was associated with transcriptional activation and mRNA stabilization, suggesting a dual molecular mechanism of control. Iron chelation could be involved in MIPs induction by PA because iron sulfate inhibited the process and the iron-chelating agent, desferrioxamine, induced MIPs expression. We propose the existence of a new pathway leading to inflammation initiated by tryptophan catabolism that can communicate with the immune system through the production of PA, followed by secretion of chemokines by macrophages. These results establish the importance of PA as an activator of macrophage proinflammatory functions, providing the first evidence that this molecule can be biologically active without the need for a costimulatory agent.

The recruitment of inflammatory cell populations to sites of injury or infection is driven by the local secretion of appropriate chemotactic signals (1). In the past few years, a rapidly expanding group of small chemotactic proteins, referred to as the chemokine superfamily, has been identified and characterized (2). The chemokine superfamily has been subdivided into four distinct classes, which differ with respect to the number and arrangement of the conserved cysteine residues at the N terminus of the primary amino acid sequence (CXC or α, CC or β, C or γ, and CX3C or δ) and are encoded by different sets of genes clustered on separate chromosomes (2, 3, 4). Chemokines are produced by both immune and nonimmune cells in response to inflammatory stimuli or tissue damage (5, 6, 7, 8, 9, 10, 11) and are involved in an impressive array of immunoregulatory and inflammatory functions, including leukocyte migration and activation (12, 13, 14), myelopoiesis, and neoangiogenesis (3, 4).

A primary source for chemokines are activated mononuclear phagocytes, which are important mediators of cellular immunity against infections and tumors (15, 16), acting directly through the release of effector molecules (15) or indirectly by recruiting T lymphocytes and NK cells to target tissues through the release of chemokines (10, 17). The extent and magnitude of a local macrophage response are regulated by an interplay of stimulatory and inhibitor signals of various nature that include cytokines and metabolites produced by surrounding cells (16), microbial products present in an inflammatory environment (10, 18), or tissue-selective factors, such as changes in O2 tension and pH (19, 20). However, the contribution of stimuli not directly derived from the immune system to the induction of chemokines has not been fully elucidated.

Recent studies have suggested a role for amino acid catabolites as important signals for mononuclear phagocyte physiology. The metabolism of two essential amino acids, l-tryptophan (l-TRP)3 and l-arginine, for instance, has been associated with the tumoricidal and microbicidal activities of murine macrophages (21). Enhanced breakdown of l-TRP has been demonstrated in inflammatory reactions and implicated in antimicrobial activity, T cell tolerance, and in some of the biological effects of IFN-γ (22, 23, 24, 25), and increased expression of indoleamine 2,3-dioxygenase (IDO), the inducible enzyme controlling l-TRP catabolic pathway in extrahepatic tissues (26), was detected in inflammatory lesions and placenta (21, 23, 24, 27). l-TRP catabolism, initiated either by IDO or epatic enzymes, leads to the production of metabolites, some of which are biologically active molecules (21). Among them, PA, an end-product of l-TRP degradation (28) detected in human milk, pancreatic juice, and intestine (29, 30), is endowed with important immunomodulatory properties involving activation of mononuclear phagocyte effector functions (31). This molecule is a potent costimulus for induction of macrophage-mediated cytotoxicity, able to inhibit tumor growth in tumor-bearing mice through the stimulation of macrophage tumoricidal activity (32, 33). PA may also contribute to the microbicidal activity of macrophages in vivo. Intraperitoneal and intracerebral administration of this metabolite protects mice against a lethal intracerebral challenge with the opportunistic pathogen Candida albicans (34). Moreover, PA, in combination with IFN-γ, inhibits retrovirus expression in macrophages, both in vitro (35) and in vivo (31), and triggers the transcriptional activation of the inducible isoform of the NO synthase gene, stimulating production of NO (36), a major effector molecule implicated in the expression of macrophage tumoricidal and microbicidal activities (37).

Despite the growing body of evidence demonstrating the importance of PA for the activation of macrophage lytic activities, there is currently little information on its effects on mononuclear phagocyte proinflammatory functions. Because increased catabolism of tryptophan appears to be correlated to the inflammatory response, the present study was designed to determine whether PA could trigger macrophage expression of chemokines and thus contribute to the onset of inflammation. To address this issue, we analyzed the expression pattern of several α- and β-chemokine mRNA in both mouse peritoneal macrophages and in the murine macrophage cell line ANA-1 in response to PA stimulation. The data presented in this study demonstrate for the first time that PA alone can potently and selectively induce the coordinated expression of the CC-chemokines macrophage inflammatory protein-1α (MIP-1α) and MIP-1β (MIPs) mRNA in murine macrophages.

Materials and Methods

Cells and culture conditions

The mouse macrophage cell line ANA-1 was established by infecting bone marrow-derived cells from C57BL/6 mice with the J2 recombinant retrovirus, carrying the v-raf/v-myc oncogenes (38), and was shown to display the phenotypic and functional features and the morphology of well-differentiated macrophages (36, 38). ANA-1 macrophages were cultured in DMEM (ICN Biomedicals, Aurora, OH) supplemented with 10% heat-inactivated FCS (HyClone Laboratories, Logan, UT), 2 mM l-glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin (Celbio, Milan, Italy). Peritoneal macrophages were obtained from C57BL/6 mice injected i.p. with 1 ml of 3% thioglycolate broth (Sigma, St. Louis, MO). After 4 days, the peritoneal exudate cells were collected by lavage of the peritoneal cavity with 10 ml of sterile PBS (ICN Biomedicals). Cells were washed, resuspended, and plated in RPMI 1640 (ICN Biomedicals) supplemented as described above. Macrophages were isolated by adherence to tissue culture dishes, and their purity was about 94%, as assessed by morphology on Giemsa-stained cytocentrifuge slide preparations. Viability, determined by trypan blue dye exclusion test, was greater than 99%. Cells were maintained at 37°C in a humidified incubator containing 20% O2, 5% CO2, and 75% N2. For experimental purpose, macrophages were cultured in 15-cm Costar plates (Costar, Cambridge, MA) at 1 × 106 cells/ml, and stimulated for different time points with the indicated factors. Special care was taken to ensure LPS-free conditions in all the experiments.

Reagents

Mouse IFN-γ (sp. act. ≥ 107 U/mg) was purchased from Life Technologies (Gaithersburg, MD). LPS (from Escherichia coli serotype 011:B4) was purchased from Sigma. PA, desferrioxamine, and ferrous sulfate were from Sigma. During the course of experiments, several batches of PA were used, and all of them gave consistent and reproducible results. PA was dissolved in PBS, and the pH was adjusted to 7.4. The stock solution was then passed through a 0.2-μm filter, aliquoted, and stored at −20°C. Actinomycin D (ActD; Calbiochem-Novabiochem, La Jolla, CA) was dissolved in ethanol at 1 mg/ml and used at a final concentration of 5 μg/ml for the times specified in the text. Cycloheximide (Sigma) was used at 7.5 μg/ml final concentration. The content of endotoxin, as determined by assay with a chromogenic Limulus amebocyte lysate test (QCL-1000; BioWhittaker, Walkersville, MD), was below the detection limit of 6 pg/ml in all of the reagents used.

RNase protection assay (RPA)

Total RNA was extracted from ANA-1 macrophages using the Trizol isolation reagent (Life Technologies) and subjected to RPA analysis using the RiboQuant MultiProbe RPA System from PharMingen (San Diego, CA), according to the manufacturer’s instruction. Briefly, a 32P-labeled antisense RNA probe set specific for different mouse α/β-chemokines (Mouse Chemokine Template Set, mCK-5) was hybridized in excess to 10 μg of total RNA from each sample in solution, after which free probe and other ssRNA were digested with RNases. The remaining RNase-protected probes, annealed to homologous sequences in the sample RNA, were purified by ethanol precipitation and resolved on denaturing PAGE. Following separation by PAGE, protected 32P-labeled probe fragments were visualized by film autoradiography (Kodak XAR-5 films; Eastman Kodak, Rochester, NY): the presence of the target mRNA in the sample was revealed by the appearance of an appropriately sized fragment of the probe. For quantification, autoradiographs were scanned using a light densitometer (PhosphorImager; Molecular Dynamics, Sunnyvale, CA).

Northern blot analysis

Total cellular RNA was purified from ANA-1 macrophages and from thioglycolate-elicited peritoneal macrophages using the Trizol RNA reagent (Life Technologies), according to the manufacturer’s instructions. A total of 20 μg of RNA from each sample was electrophoresed under denaturing conditions on a 1.2% agarose gel containing 2.2 M formaldehyde, transferred onto Nytran membranes (Schleicher & Schuell, Keene, NH), and cross-linked by UV irradiation. Filters were hybridized with 32P-labeled probes and autoradiographed, as previously described (36). Different times of exposure were used to obtain comparable levels of band intensities with different probes. For MIP-1α and MIP-1β detection, the mouse MIP-1α and MIP-1β full-length cDNAs from the pBR322 vector, kindly provided by Dr. Antonio Sica (Istituto Mario Negri, Milan, Italy), were used. For MCP-1 detection, the full-length JE cDNA from the pUC19 vector, obtained from Dr. Antonio Sica, was used. The pBluescript II SK(−) vector containing the mouse MDC cDNA was gently provided by Dr. Silvano Sozzani (Istituto di Ricerche Farmacologiche “Mario Negri,” Milan, Italy). The pEMBL-8 vector containing the β-actin cDNA was kindly provided by Dr. Cecilia Garré (Istituto di Biologia e Genetica, Facoltá di Medicina e Chirurgia, Universitá di Genova, Italy).

Nuclear run-on experiments

Nuclear run-on experiments were performed, as previously described (36). Briefly, nuclei were isolated from 10 × 107 cells/sample by cell lysis and collected by centrifugation. In vitro RNA elongation was performed by adding 2× transcription buffer and 100 μCi of 800 Ci/mmol [α-32P]uridine triphosphate (NEN, Boston, MA) to the nuclei suspension, incubating the mixture at 29°C for 30 min, and for additional 10 min at 30°C after addition of CaCl2 and RNase-free DNase I (Promega, Gaithersburg, MD). Nuclei were lysed with 1 ml Trizol, and total RNA was isolated according to the manufacturer’s procedure. Equal amounts of labeled elongated transcripts were added in Hybrisol solution to Nytran membranes, on which denatured pBR322 plasmid containing the full-length MIP-1α cDNA or the full-length MIP-1β cDNA, denatured pEMBL plasmid containing the full-length β-actin, and EcoRI-linearized pBR322 were immobilized using a dot-blot apparatus (Bio-Rad Laboratories, Hercules, CA). Hybridization was performed at 42°C for 48 h, and filters were then washed as described for Northern analysis. When needed, the autoradiographs were scanned using a light densitometer.

Results

PA is a potent and selective inducer of MIP-1α and MIP-1β mRNA expression in mouse macrophages

Initial experiments were designed to study the effects of PA in regulating the expression pattern of several α- and β-chemokine mRNA in the murine macrophage cell line ANA-1. Cells were cultured for 18 h in medium alone, supplemented with PA, or LPS as a positive control (2, 10). MultiProbe RPA was then performed on total RNA preparations to analyze the expression of distinct chemokine transcripts (Fig. 1⇓). We found little or no constitutive expression of the mRNA for the β-chemokines monocyte chemoattractant protein (MCP-1/JE), MIP-1α, MIP-1β, and RANTES, and the α-chemokines IFN-γ-inducible protein-10 and macrophage inflammatory protein-2 (MIP-2). PA caused a significant up-regulation of MIP-1α and MIP-1β (MIPs) mRNA without affecting the levels of the other chemokine mRNAs, providing the first suggestion that PA alone can induce gene expression in macrophages and differentially modulate the expression of different chemokine mRNA. As previously reported (2, 10), LPS strongly induced the expression of the message for all of the chemokines tested.

FIGURE 1.
FIGURE 1.

RPA analysis of chemokine mRNA expression in ANA-1 macrophages. Total RNA was extracted from ANA-1 cells stimulated for 18 h with medium, PA (4 mM), or LPS (10 ng/ml), hybridized with a set of 32P-labeled mouse chemokine-specific antisense RNA probes, and analyzed by electrophoresis, as described in Materials and Methods. The GAPDH probe is used as a control of RNA loading. Data shown are from one representative experiment of three performed.

To strengthen these conclusions, Northern blot analysis was performed on total RNA isolated from ANA-1 macrophages stimulated for 18 h with medium alone or containing 4 mM PA. As shown in Fig. 2⇓A, low constitutive levels of MIPs mRNA were detectable, although MIP-1β seemed less expressed than MIP-1α because longer blot exposure was required to obtain bands of comparable intensity. PA treatment caused a major enhancement of MIP-1α and MIP-1β mRNAs. MIPs mRNA induction, ranging from 8- to 15-fold, was consistently observed in five independent experiments performed, although slight fluctuations in the baseline levels were detected. Under the same conditions, PA did not affect the constitutive expression of MCP-1 mRNA (Fig. 2⇓A). To determine whether this response was a general consequence of macrophage activation, the effects of other macrophage activators, IFN-γ (100 IU/ml) or LPS (10 ng/ml), on MIPs mRNA levels were also investigated. IFN-γ failed to increase MIPs expression, while potently inducing MCP-1 mRNA accumulation, whereas LPS greatly up-regulated the expression of all three chemokines tested (Fig. 2⇓A).

FIGURE 2.
FIGURE 2.

PA specifically up-regulates the constitutive expression of MIP-1α and MIP-1β in mouse macrophages. A, Total RNA was isolated from ANA-1 cells treated for 18 h with 4 mM PA, 100 IU/ml IFN-γ, or 10 ng/ml LPS, and analyzed by Northern blotting. B, Total RNA from ANA-1 cells treated for 18 h with 4 mM PA, or 10 ng/ml LPS was analyzed for MDC expression. C, Thioglycolate-elicited mouse peritoneal macrophages were stimulated for 18 h with medium alone or supplemented with 4 mM PA, and Northern blot analysis was performed on total RNA. The blots were sequentially hybridized with the cDNAs for the indicated chemokines. β-Actin levels were determined to ensure that comparable amounts of RNA were loaded in each lane. Blots hybridized with MIP-1α and MIP-1β cDNAs were exposed for 4 and 24 h, respectively, to obtain comparable band intensities.

The selective stimulatory activity of PA on MIPs was further confirmed by the demonstration that PA did not affect the low constitutive mRNA expression of the murine macrophage-derived chemokine, MDC, a CC chemokine typically produced by mature macrophages (39, 40), that was up-regulated by LPS (Fig. 2⇑B).

Thioglycolate-elicited peritoneal exudate macrophages from C57BL/6 mice were analyzed to extend the results obtained with ANA-1 cells to primary macrophage cultures. Control macrophages expressed low constitutive levels of MIPs mRNA (Fig. 2⇑C). Stimulation with PA increased MIP-1α and MIP-1β mRNA accumulation, although to a lesser extent than in ANA-1 cells. A similar pattern of results was consistently observed in three independent experiments, with the induction ranging from 4- to 8-fold over control.

The kinetics of MIP-1α and MIP-1β mRNA induction by PA is shown in Fig. 3⇓A. MIP-1α and MIP-1β transcripts were detectable as early as 3 and 6 h after treatment, respectively, reached plateau levels at 12–24 h, and declined thereafter.

FIGURE 3.
FIGURE 3.

Time- and dose-dependent induction of MIP-1α and MIP-1β mRNA expression by PA. ANA-1 macrophages were cultured for different time points with 4 mM PA (A) or for 12 h with increasing concentrations of PA (B), and total RNA was assayed for MIP-1α and MIP-1β expression by Northern blotting. The blots were then exposed for 4 and 24 h, respectively, to obtain comparable band intensities, and then rehybridized with the β-actin probe to control the RNA loading.

To determine the dose dependence of PA effects, MIP-1α and MIP-1β mRNA expression was assessed after stimulation for 12 h with increasing amounts of PA (Fig. 3⇑B). Plateau levels of expression were obtained with 4 mM PA, a dose previously shown to be optimal for mouse macrophage activation (36). At the concentrations used, PA did not affect cell viability, as determined by the trypan blue dye exclusion test (data not shown).

These results provide the first evidence that PA is a potent and selective inducer of MIP-1α and MIP-1β mRNA expression in murine macrophages.

PA augments the transcriptional activity of MIP-1α and MIP-1β genes and enhances the mRNA stability of both chemokines

Run-on experiments were conducted on nuclei isolated from ANA-1 cells stimulated for 4 h (Fig. 4⇓A) or 6 h (Fig. 4⇓B) with medium alone, PA, or LPS, to study the mechanism responsible for MIP-1α and MIP-1β mRNA induction. MIP-1α gene was transcriptionally active in medium-treated cells, and susceptible to augmentation in response to LPS. A 2.6-fold increase in the rate of MIP-1α gene transcription was observed in cells stimulated with PA for 4 h (A) or 6 h (B). In contrast, constitutive transcription of MIP-1β gene was not detected, and induction of transcription was not observed after 4 h (A), but only after 6 h (B) of treatment with PA. In conclusion, the up-regulation of MIPs mRNA expression by PA was associated with the transcriptional activation of the genes, although the kinetics of MIP-1β induction was delayed compared with that of MIP-1α.

FIGURE 4.
FIGURE 4.

Effects of PA on MIP-1α and MIP-1β gene transcriptional activity. ANA-1 cells were treated with medium alone, PA (4 mM), or LPS (10 ng/ml), nuclei were isolated after 4 h (A) and 6 h (B), and the rate of transcription of MIP-1α and MIP-1β genes was determined by nuclear run-on analysis, as detailed in Materials and Methods, using the pBR322 plasmid containing the mouse MIP-1α or MIP-1β cDNA inserts. PBR322, Denotes the vector lacking any cDNA insert; β-actin, indicates the pEMBL8 plasmid containing a chicken β-actin cDNA insert. The results depicted are from one representative experiment of three performed. Left panels, Run-on analysis of MIPs gene transcription. Right panels, Quantitative analysis of MIPs gene transcription: results from PhosphorImager analysis of the filters are presented as a bar graph. The relative level of de novo transcription for each sample was determined after subtracting the background hybridization and following normalization of the band intensities to the respective amounts of β-actin.

To measure the stability of MIP-1α/β mRNA induced by PA, ANA-1 cells were incubated in the presence or absence of PA for 12 h, and mRNA expression was tested immediately or after addition of 5 μg/ml of ActD for the indicated lengths of time to block further RNA transcription. As indicated in Fig. 5⇓, MIPs mRNAs decayed with different kinetics in untreated and PA-treated cells. The levels of MIP-1α and MIP-1β transcripts in unstimulated macrophages decreased by 50% (t1/2) after 2.5 and 1.2 h, respectively. PA-treated cells displayed a greater MIPs mRNA stability. The t1/2 of MIP-1α mRNA was increased to more than 8 h, whereas that of MIP-1β was increased to 2 h by PA. In addition, 30% of MIP-1β mRNA was still detectable after 8 h of exposure to ActD in PA-treated cells, whereas in control cells it became undetectable after 4 h of exposure to the drug. We concluded that PA stabilized MIP-1α and to a lesser extent MIP-1β mRNAs.

FIGURE 5.
FIGURE 5.

PA enhances MIP-1α and MIP-1β mRNA stability in ANA-1 macrophages. A, Cells were treated with medium alone or containing PA (4 mM) for 12 h, and ActD (5 μg/ml) was then added to the culture. Total RNA was harvested after 1, 2, 4, 6, and 8 h, and Northern blot analysis was performed. Blots were sequentially hybridized with MIP-1α and MIP-1β cDNAs and exposed for 4 and 24 h, respectively. β-actin levels were determined to ensure that comparable amounts of RNA were loaded in each lane. B, Data are presented as the relative amounts of MIP-1α or MIP-1β mRNA remaining after addition of ActD and normalization to the respective amounts of β-actin.

To determine whether de novo protein synthesis was required for PA-induced expression of MIPs mRNA, ANA-1 cells were treated for 12 h with PA in the presence or absence of 7.5 μg/ml of the protein synthesis inhibitor cycloheximide (CHX). Under these experimental conditions, CHX inhibited protein synthesis by more than 90% (data not shown). The addition of CHX to PA-treated cells completely prevented the up-regulation of both MIP-1α and MIP-1β mRNA expression (Fig. 6⇓). Similar results were observed in three independent experiments.

FIGURE 6.
FIGURE 6.

De novo protein synthesis is required for PA-induced MIP-1α and MIP-1β expression. ANA-1 macrophages were incubated for 12 h with the indicated stimuli, in the absence or presence of 7.5 μg/ml CHX, and total RNA was examined for MIP-1α and MIP-1β expression by Northern blot.

Taken together, these results indicate that PA-dependent up-regulation of MIP-1α and MIP-1β mRNA in ANA-1 macrophages is controlled through a dual molecular mechanism involving both the transcriptional activation of the genes and the posttranscriptional stabilization of the messages, and that it requires active protein synthesis.

Iron chelation is involved in PA-dependent induction of MIPs gene expression

It has been previously reported that the biological effects of PA involved chelation of iron (41, 42). To determine the requirement for iron chelation in PA-dependent induction of MIPs expression, ANA-1 cells were stimulated for 12 h with PA, alone or in the presence of increasing concentrations of FeSO4, and the expression of MIP-1α and MIP-1β mRNA was analyzed. One representative experiment of three performed is depicted in Fig. 7⇓A. The addition of FeSO4 caused a major and dose-dependent suppression of MIPs mRNAs in PA-stimulated macrophages, detectable at 100 μM and maximal at 300 μM. FeSO4 alone did not have any effect on the expression of MIPs mRNA at any of the concentrations tested (Fig. 7⇓A). We conclude that chelation of iron was part of the mechanism of action of PA.

FIGURE 7.
FIGURE 7.

A, Dose-dependent down-regulation of PA-induced MIP-1α and MIP-1β mRNA by FeSO4. ANA-1 macrophages were stimulated with PA (4 mM) for 12 h in combination with the indicated concentrations of FeSO4. Northern blot analysis and densitometric quantification of mRNA levels were performed. Data are presented as the relative amounts of MIP-1α or MIP-1β mRNA obtained after normalization to the respective amounts of β-actin. B, DFX specifically induces MIP-1α and MIP-1β transcripts in ANA-1 macrophages. ANA-1 cells were cultured for 12 h with 200 μM DFX, in the absence or presence of 300 μM FeSO4, and total cellular RNA was examined for the expression of MIP-1α, MIP-1β, and MCP-1 mRNA. The filter was subsequently probed with β-actin.

To further investigate the role of iron chelation in MIPs induction, we studied the effects of a synthetic iron-chelating drug, desferrioxamine (DFX), on MIP-1α and MIP-1β expression. ANA-1 macrophages were treated with DFX, and the expression of MIPs mRNA was then tested (Fig. 7⇑B). DFX selectively increased MIP-1α and MIP-1β, but not MCP-1, mRNA expression (10- to 15-fold above the baseline), and addition of FeSO4 caused a reduction in DFX-mediated MIPs up-regulation greater than 90%.

These results show that DFX is a stimulus for the induction of MIP-1α and MIP-1β in macrophages and that FeSO4 inhibits the activating properties of PA and DFX, indicating that iron chelation is involved in the regulation of MIPs expression in macrophages.

Discussion

The central role of macrophage-derived chemokines in the regulation of host immune and inflammatory responses is well established (2, 3, 4, 10, 14). However, the network of stimuli that control their production has not been fully characterized, and it extends beyond the classical signals derived from the immune system. In an attempt to identify alternative physiopathological stimuli regulating chemokine expression, we have investigated the response of mouse macrophages to PA, a l-TRP catabolite with macrophage costimulatory properties (21, 31, 33, 34, 35, 43). We found that PA is a potent and selective inducer of MIP-1α and MIP-1β mRNA in murine macrophages.

The murine macrophage cell line ANA-1 expressed low constitutive levels of MIP-1α and MIP-1β mRNA, and PA caused a major up-regulation of their expression. MIP-1α increased earlier than MIP-1β, but both chemokines reached plateau levels 12 h after PA stimulation. Slight fluctuations in the baseline levels of MIPs mRNA were observed, probably due to cell adherence to plastic (16). However, the constitutive levels of MIP-1β were lower than those of MIP-1α, even if PA induced a comparable up-regulation of the two transcripts. Similar results were observed using fresh murine peritoneal exudate macrophages, excluding an idiosyncratic behavior of the ANA-1 cell line. Interestingly, PA stimulatory activity was selective for MIP-1α and MIP-1β because it was not exerted on several other β- and α-chemokines, including MCP-1, RANTES, IFN-γ-inducible protein-10, MIP-2, and MDC. Furthermore, the augmentation of MIPs mRNA expression by PA was not a general response to macrophage stimulation. In fact, IFN-γ, a potent activator of mononuclear phagocyte functions (16, 36), did not increase MIP-1α or MIP-1β mRNA, despite its ability to induce MCP-1 expression. We can rule out the possibility that endotoxin contamination contributed to the activation of MIPs expression, because PA preparations did not contain any detectable levels of LPS, and addition of polymyxin B sulfate, which binds to and neutralizes LPS (44), did not reduce PA stimulatory activity (data not shown). Moreover, other chemokines besides MIPs were strongly induced by LPS, but not by PA. The demonstration of MIPs mRNA augmentation is the first evidence of the ability of PA alone to trigger gene expression in macrophages without the need for a costimulus.

Transcriptional activation is the primary mechanism of regulation of chemokine gene expression in different cell types (18, 45, 46, 47). Transcriptional induction of MIP-1α and MIP-1β gene expression in macrophages has been previously reported (3, 19, 48). We found that MIP-1α gene was transcriptionally active, and that stimulation with PA induced a 2.6-fold increase in its transcription already after 4 h. In contrast, activation of MIP-1β gene transcription by PA was delayed and became evident only 6 h after stimulation. These results provide the first evidence that PA by itself can induce gene transcriptional activation, and raise the issue of the promoter element(s) involved.

MIPs induction by PA is also due to the stabilization of the mRNA that decayed at a slower rate in PA-treated macrophages than in control cultures. These results are consistent with the findings that MIP-1α and MIP-1β contain variants of the AUUUA consensus sequence in their 3′ untranslated region (3, 49), present in the 3′ UTR of many cytokine genes, and controlling mRNA stability and translation (50, 51, 52). Posttranscriptional regulation of MIP-1α and MIP-1β mRNA expression in macrophages has been previously shown following stimulation by bacterial endotoxin (49), in response to oxidative stress (19) or IL-10 (47).

PA-dependent increase of MIPs mRNA was abolished by addition of protein-synthesis inhibitors, demonstrating a requirement for active protein synthesis and suggesting that MIPs expression may be controlled by a de novo synthesized transcriptional enhancer(s) and/or by a factor(s) with a short t1/2 involved in the regulation of mRNA stability.

The mechanism of action of PA is not known, although it has been reported that this agent interferes with several biochemical pathways (31). PA binds iron and interferes with iron uptake (31, 41), and iron chelation may contribute to PA activities (41, 42). In this study, we show that iron sulfate suppressed PA-induced MIP-1α and MIP-1β mRNA up-regulation, suggesting a role for iron chelation in the induction of MIPs. This conclusion is supported by the demonstration that DFX, a synthetic iron chelator (53, 54), is similar to PA in selectively inducing MIP-1α and MIP-1β mRNA, and that this effect is abrogated by iron sulfate. Induction of MIP-1α and MIP-1β by DFX may have practical clinical implications because this drug is used for the treatment of several pathological conditions, including iron overload (54), cancer (55), and Alzheimer’s disease (53), and, interestingly, several lines of evidence indicate that chemokines might contribute to the pathogenesis of these diseases (3).

In conclusion, the results presented in this study identify a novel connection between l-TRP degradation, its end-product PA, and the expression of MIP-1α and MIP-1β chemokines in macrophages, extending previous findings on the important role of l-TRP catabolism in regulating host immune mechanisms and inflammatory processes (21, 22, 25, 27, 56, 57). Expression and activation of IDO, a key enzyme in the degradation of l-TRP along the kynurenine pathway (26), in placenta and human macrophages have been associated with inhibition of T cell immune responses (24, 58). To which extent IDO activation leads to PA production and whether such pathway is relevant in mouse macrophages are currently being investigated. A recent report demonstrating that PA significantly decreases IDO expression and activity in mouse macrophages (59) suggests a role for this catabolite as an inhibitor of IDO-mediated T cell immunosuppression in local tissue microenvironment, and is consistent with our results showing the importance of PA in the activation of macrophage proinflammatory functions.

The levels of PA detected in vivo in biological fluids varies from 3 (30) to 300 μM (29), and we have measured micromolar concentrations of PA (from 10 to 80 μM) in the serum of patients with chronic liver diseases (Dazzi, et al., submitted manuscript4), although the concentrations of PA in tissues are still unknown. The stimulatory effects of PA in vitro require concentrations of about 2–4 mM (36 and this study), and our unpublished observations indicate that millimolar concentrations of PA are necessary in vitro to achieve detectable intracellular quantities of PA in ANA-1 macrophages (detection limit 100 pM). Levels of PA higher than those detected in human serum may be achieved in vivo in the intercellular space or could be locally produced during inflammatory responses, as suggested by elevation of l-TRP catabolites in localized compartments under pathologic conditions (60). Moreover, it is possible that the in vivo environment may alter the accessibility of PA to the cell, decreasing the biologically active concentration. In fact, the association of PA with serum proteins and/or with divalent cations (41) may modify the permeability of the compound. Finally, the possibility exists that PA may act endogenously in the producing cells and that its biologic activity may not correlate with the circulating levels.

MIP-1α and MIP-1β are important mediators of the inflammatory reactions (3, 12, 13) and potent T cell chemoattractants, able to regulate T cell trafficking during an immune response in vivo (3, 4, 14, 61). The modulation of MIPs expression is a crucial set point for the control of the kinetics and composition of the cellular infiltrate in target tissues (3, 17). The demonstration that PA can induce MIP-1α and MIP-1β expression indicates that this molecule can regulate the inflammatory response at multiple levels. In a simplistic view, PA alone elicits MIPs chemokine expression in macrophages and, consequently, T cell recruitment, and, in conjunction with T cell products such as IFN-γ, triggers the fully activated phenotype.

It was recently demonstrated that MIP-1α and MIP-1β can inhibit HIV-1 infection by binding to their receptor CCR5, which functions as a cell membrane fusion cofactor with CD4 for the virus gp120 envelope protein, and, thus, by blocking HIV-1 entry into the cells (62, 63). Schmidtmayerova et al. (64) showed elevated levels of MIP-1α/β expression in HIV-1-infected monocytes and in microglia and astrocytes from the brain tissue of patients with HIV encephalitis. On the other hand, decreased levels of circulating l-TRP and accumulation of l-TRP catabolites, such as kynurenine and quinolinic acid, have been detected in the cerebrospinal fluid of patients infected with HIV-1, particularly in those with neurologic deficits and AIDS dementia complex (25, 65). These results raise questions on the role of l-TRP catabolites in AIDS, particularly of PA that, by up-regulating MIPs expression, could exert protective effects on the host. Evaluation of PA levels in the fluids of AIDS patients is currently underway.

Acknowledgments

We thank Dr. Antonio Sica (Istituto di Ricerche Farmacologiche “Mario Negri,” Milan, Italy) for kindly providing the pBR322 vector containing the mouse MIP-1α and MIP-1β full-length cDNAs and the pUC19 vector containing the full-length JE cDNA; Dr. Silvano Sozzani (Istituto di Ricerche Farmacologiche “Mario Negri”) and Dr. Cecilia Garré (Institute of Biology and Genetic (IBiG), Facoltá di Medicina e Chirurgia, Universitá di Genova, Genova, Italy) for kindly providing the pBluescript II SK(−) vector containing the mouse MDC cDNA and the pEMBL-8 vector containing the β-actin cDNA, respectively. We also thank Fulvia Lerone for editing the manuscript.

Footnotes

  • ↵1 This work was supported by grants from the Italian Association for Cancer Research (AIRC), the Telethon Italy (Project A75), Associazione Italiana Lotta Neuroblastoma, and the Centro Nazionale Ricerche.

  • ↵2 Address correspondence and reprint requests to Dr. Maria Carla Bosco, Laboratorio di Biologia Molecolare, Istituto Giannina Gaslini, L.go Gerolamo Gaslini 5, 16147 Genova Quarto, Italy. E-mail address: mcbosco{at}tin.it

  • ↵3 Abbreviations used in this paper: l-TRP, l-tryptophan; ActD, actinomycin D; CHX, cycloheximide; DFX, desferrioxamine; IDO, indoleamine 2,3-dioxygenase; MCP, monocyte chemoattractant protein; MDC, macrophage-derived chemokine; MIP, macrophage inflammatory protein; PA, picolinic acid; RPA, RNase protection assay.

  • ↵4 C. Dazzi, G. Candiano, A. Ponzetto, and L. Varesio. A new HPLC method for the detection of picolinic acid, a catabolite of l-tryptophan, in biological fluids. Submitted for publication.

  • Received August 27, 1999.
  • Accepted January 3, 2000.

References

  1. ↵
    Ben-Baruk, A., D. Michiel, J. Oppenheim. 1995. Signals and receptor involved in recruitment of inflammatory cells. J. Biol. Chem. 270: 11703
    OpenUrlFREE Full Text
  2. ↵
    Baggiolini, M., B. Dewald, B. Moser. 1994. Interleukin 8 and related chemotactic cytokines: CXC and CC chemokines. Adv. Immunol. 55: 97
    OpenUrlPubMed
  3. ↵
    Schall, T.. 1991. Biology of RANTES/SIS cytokine family. Cytokine 3: 165
    OpenUrlCrossRefPubMed
  4. ↵
    Murphy, P.. 1996. Chemokine receptors: structure, functions and role in microbial pathogenesis. Cytokine Growth Factor Rev. 7: 47
    OpenUrlCrossRefPubMed
  5. ↵
    Selvan, R. S., H. B. Kapadia, J. L. Platt. 1998. Complement-induced expression of chemokine genes in endothelium: regulation by IL-1-dependent and -independent mechanisms. J. Immunol. 161: 4388
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Bluman, E. M., K. J. Bartynski, B. R. Avalos, M. A. Caligiuri. 1996. Human natural killer cells produce abundant macrophage inflammatory protein-1α in response to monocyte-derived cytokines. J. Clin. Invest. 97: 2722
    OpenUrlCrossRefPubMed
  7. ↵
    Krzysiek, R., E. A. Lefèvre, W. Zou, A. Foussat, J. Bernard, A. Portier, P. Galanaud, Y. Richard. 1999. Antigen receptor engagement selectively induces macrophage inflammatory protein-1α (MIP-1α) and MIP-1β chemokine production in human B cells. J. Immunol. 162: 4455
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Rathanaswami, P., M. Hachicha, M. Sadick, T. J. Shall, S. R. McColl. 1993. Expression of the cytokine RANTES in human rheumatoid synovial fibroblast. J. Biol. Chem. 268: 5834
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Bliss, S. K., A. J. Marshall, Y. Zhang, E. Y. Denkers. 1999. Human polymorphonuclear leukocytes produce IL-12, TNF-α, and the chemokines macrophage-inflammatory protein-1α and -1β in response to Toxoplasma gondii antigens. J. Immunol. 162: 7369
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Kopydlowski, K. M., C. A. Salkowski, M. J. Cody, N. Van Rooijen, J. Major, T. A. Hamilton, S. N. Vogel. 1999. Regulation of macrophage chemokine expression by lipopolysaccharide in vitro and in vivo. J. Immunol. 163: 1537
    OpenUrlAbstract/FREE Full Text
  11. ↵
    McManus, C. M., C. F. Brosnam, J. W. Berman. 1998. Cytokine induction of MIP-1α and MIP-1β in human fetal microglia. J. Immunol. 160: 1449
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Taub, D., T. J. Sayers, C. R. D. Carter, J. Ortaldo. 1995. α and β chemokines induce NK cell migration and enhance NK-mediated cytolysis. J. Immunol. 155: 3877
    OpenUrlAbstract
  13. ↵
    DiPietro, L. A., M. D. Burdick, Q. E. Low, S. Kunkel, R. Strieter. 1998. MIP-1α as a critical macrophage chemoattractant in murine wound repair. J. Clin. Invest. 101: 1693
    OpenUrlCrossRefPubMed
  14. ↵
    Siveke, J. T., A. Hamann. 1998. Cutting edge: T helper 1 and T helper 2 cells respond differentially to chemokines. J. Immunol. 160: 550
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Adams, D., T. Hamilton. 1988. Phagocytic cells. Cytotoxic activities of macrophages. B. B. Aggarwal, and R. K. Puri, eds. Inflammation: Basic Principles and Clinical Correlates 471 Blackwell Scientific Publication, Cambridge.
  16. ↵
    Varesio, L., I. Espinoza-Delgado, G. Gusella, G. Cox, G. Melillo, T. Musso, M. C. Bosco. 1995. Role of cytokines in the activation of monocytes. B. B. Aggarwal, and R. K. Puri, eds. Human Cytokines: Their Role in Disease and Therapy 55 Blackwell Scientific Publication, Cambridge.
  17. ↵
    Schrum, S., P. Probst, B. Fleischer, P. F. Zipfel. 1996. Synthesis of the CC-chemokines MIP-1α, MIP-1β, and RANTES is associated with a type 1 immune response. J. Immunol. 157: 3598
    OpenUrlAbstract
  18. ↵
    Horton, M. R., C. M. McKee, C. Bao, F. Liao, J. M. Farber, J. Hodge-DuFour, E. Puré, B. L. Oliver, T. M. Wright, P. W. Noble. 1998. Hyaluronan fragments synergize with interferon-γ to induce the CXC chemokines Mig and interferon-inducible protein-10 in mouse macrophages. J. Biol. Chem. 273: 35088
    OpenUrlAbstract/FREE Full Text
  19. ↵
    Shi, M. M., J. J. Godleski, J. D. Paulauskis. 1996. Regulation of macrophages inflammatory protein-1α mRNA by oxidative stress. J. Biol. Chem. 271: 5878
    OpenUrlAbstract/FREE Full Text
  20. ↵
    Melillo, G., S. Lynn, B. Taylor, A. Brooks, G. Cox, L. Varesio. 1996. Regulation of inducible nitric oxide synthase expression in IFN-γ-treated murine macrophages cultured under hypoxic conditions. J. Immunol. 157: 2638
    OpenUrlAbstract
  21. ↵
    Varesio, L., G. Cox, K. Pulkki, A. Brooks, G. Melillo. 1992. Arginine and tryptophan catabolism: the picolinic acid connection. I. Ishiguro, and R. Kido, and T. Nagatsu, and Y. Nagamura, and Y. Ohta, eds. Advances in Tryptophan Research 309 Fujita Health University Press, Tokyo.
  22. ↵
    Murray, H. W., A. Szuro-Sudol, D. Wellner, M. J. Oca, A. M. Granger, D. M. Libby, C. D. Rothermel, B. J. Rubin. 1989. Role of tryptophan degradation in respiratory burst-independent antimicrobial activity of γ interferon-stimulated human macrophages. Infect. Immun. 57: 845
    OpenUrlAbstract/FREE Full Text
  23. ↵
    Taylor, W. M., F. Gensheng. 1991. Relationship between interferon-γ, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J. 5: 2516
    OpenUrlAbstract
  24. ↵
    Munn, D. H., M. Zhou, J. Attwood, I. Bondarev, S. Conway, B. Marshall, C. Brown, A. Mellor. 1998. Prevention of allogenic fetal rejection by tryptophan catabolism. Science 281: 1191
    OpenUrlAbstract/FREE Full Text
  25. ↵
    Brown, R. R., Y. Ozaki, S. P. Datta, E. C. Borden, P. M. Sondel, D. G. Malone. 1991. Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. Adv. Exp. Med. Biol. 294: 425
    OpenUrlCrossRefPubMed
  26. ↵
    Dai, W., S. L. Gupta. 1990. Molecular cloning, sequencing and expression of human interferon-γ-inducible indoleamine 2,3-dioxygenase cDNA. Biochem. Biophys. Res. Commun. 168: 1
    OpenUrlCrossRefPubMed
  27. ↵
    Ozaki, Y., M. P. Edelstein, D. S. Duch. 1988. Induction of indoleamine 2,3-dioxygenase: a mechanism of the antitumor activity of interferon γ. Proc. Natl. Acad. Sci. USA 85: 1242
    OpenUrlAbstract/FREE Full Text
  28. ↵
    Mehler, A.. 1956. Formation of picolinic and quinolinic acids following enzymatic oxidation of 3-hydroxyanthranilate to quinolate. J. Biol. Chem. 218: 241
    OpenUrlFREE Full Text
  29. ↵
    Evans, G. W., P. E. Johnson. 1980. Characterization and quantitation of a zinc binding ligand in human milk. Pediatr. Res. 14: 867
    OpenUrl
  30. ↵
    Rebello, T., B. Lonnerdal, L. Hurley. 1982. Picolinic acid in milk, pancreatic juice and intestine: inadequate for role in zinc absorpion. Am. J. Clin. Nutr. 35: 1
    OpenUrlAbstract/FREE Full Text
  31. ↵
    Varesio, L., A. Soleti, D. Radzioch, K. Pulkki, A. Brooks, G. Gusella, M. C. Bosco, G. Forni. 1994. Picolinic acid and its influence on the immune system. H. S. Walter Kochen, ed. l-Tryptophan: Current Prospects in Medicine and Drug Safety 99 Walter de Gruyter, Berlin.
  32. ↵
    Leuthauser, S. W., L. W. Oberley, T. D. Oberley. 1982. Antitumor activity of picolinic acid in CBA/J mice. J. Natl. Cancer Inst. 68: 123
    OpenUrlAbstract/FREE Full Text
  33. ↵
    Ruffmann, R., R. Schlick, M. Chirigos, W. Budzynsky, L. Varesio. 1987. Antiproliferative activity of picolinic acid due to macrophage activation. Drugs Exp. Clin. Res. 13: 607
    OpenUrlPubMed
  34. ↵
    Blasi, E., D. Bauer, R. Barluzzi, R. Mazzolla, F. Bistoni. 1994. Pattern of cytokine gene expression in brains of mice protected by picolinic acid against lethal intracerebral infection with Candida albicans. J. Neuroimmunol. 52: 205
    OpenUrlCrossRefPubMed
  35. ↵
    Blasi, E., D. Radzioch, L. Varesio. 1988. Inibition of retroviral mRNA expression in the murine macrophage cell line GG2EE by biologic response modifiers. J. Immunol. 141: 2153
    OpenUrlAbstract/FREE Full Text
  36. ↵
    Melillo, G., G. Cox, A. Biragyn, L. Sheffler, L. Varesio. 1994. Regulation of nitric oxide synthase mRNA expression by interferon γ and picolinic acid. J. Biol. Chem. 269: 8128
    OpenUrlAbstract/FREE Full Text
  37. ↵
    Nathan, C. F., J. B. Hibbs. 1991. Role of nitric oxide synthesis in macrophage antimicrobial activity. Curr. Opin. Immunol. 3: 65
    OpenUrlCrossRefPubMed
  38. ↵
    Cox, G., B. Mathieson, L. Gandino, E. Blasi, D. Radzioch, L. Varesio. 1989. Heterogeneity of hematopoietic cells immortalizated by v-myc/v-raf recombinant retrovirus infection of bone marrow or fetal liver. J. Natl. Cancer Inst. 81: 1492
    OpenUrlAbstract/FREE Full Text
  39. ↵
    Bonecchi, R., S. Sozzani, J. T. Stine, W. Luini, G. D’Amico, P. Allavena, D. Chantry, A. Mantovani. 1998. Divergent effects of interleukin-4 and interferon-γ on macrophage-derived chemokine production: an amplification circuit of polarized T helper-2 responses. Blood 92: 2668
    OpenUrlAbstract/FREE Full Text
  40. ↵
    Rodenburg, R. J. T., R. F. B. Brinkhuis, R. Peek, J. R. Westphal, F. H. J. Van Den Hoogen, W. J. Van Venrooij, L. B. A. Van De Putte. 1998. Expression of macrophage-derived chemokine (MDC) mRNA in macrophages is enhanced by interleukin-1β, tumor necrosis factor α, and lipopolysaccharide. J. Leukocyte Biol. 63: 606
    OpenUrlAbstract
  41. ↵
    Fernandez-Pol, J.. 1977. Iron: possible cause of the G1 arrest induced by picolinic acid. Biochem. Biophys. Res. Commun. 78: 136
    OpenUrlCrossRefPubMed
  42. ↵
    Melillo, G., B. Taylor, A. Brooks, T. Musso, G. Cox, L. Varesio. 1996. Functional requirement of the hypoxia responsive element in the activation of the inducible nitric oxide synthase promoter by iron chelator desferrioxamine. J. Biol. Chem. 272: 12236
    OpenUrlAbstract/FREE Full Text
  43. ↵
    Melillo, G., T. Musso, A. Sica, L. S. Taylor, G. Cox, L. Varesio. 1995. A hypoxia responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J. Exp. Med. 182: 1683
    OpenUrlAbstract/FREE Full Text
  44. ↵
    Morrison, D. C., D. M. Jacobs. 1976. Binding of polymyxin B to the lipid A portion of bacterial lipopolysaccharide. Immunochemistry 13: 813
    OpenUrlCrossRefPubMed
  45. ↵
    Mukaida, N., Y. Mahe, K. Matsushima. 1990. Cooperative interaction of nuclear factor-κB- and cis-regulatory enhancer binding protein-like factor binding elements in activating the interleukin-8 gene by proinflammatory cytokines. J. Biol. Chem. 265: 21128
    OpenUrlAbstract/FREE Full Text
  46. ↵
    Valente, A. J., J. Xie, M. Abramova, U. Wenzel, H. Abbound, D. Graves. 1998. A complex element regulates IFN-γ-stimulated monocyte chemoattractant protein-1 gene transcription. J. Immunol. 161: 3719
    OpenUrlAbstract/FREE Full Text
  47. ↵
    Horton, M. R., M. D. Burdick, R. Strieter, C. Bao, P. W. Noble. 1998. Regulation of hyaluronan-induced chemokine gene expression by IL-10 and IFN-γ in mouse macrophages. J. Biol. Chem. 160: 3023
    OpenUrl
  48. ↵
    Widmer, U., K. R. Manogue, A. Cerami, B. Sherry. 1993. Genomic cloning and promoter analysis of macrophage inflammatory protein (MIP)-2, MIP-1α, and MIP-1β, members of the chemokine superfamily of proinflammatory cytokines. J. Immunol. 150: 4996
    OpenUrlAbstract/FREE Full Text
  49. ↵
    Shi, M. M., J. J. Godleski, J. D. Paulauskis. 1995. Molecular cloning and posttranscriptional regulation of macrophage inflammatory protein-1α in alveolar macrophages. Biochem. Biophys. Res. Commun. 211: 289
    OpenUrlCrossRefPubMed
  50. ↵
    Bosco, M. C., G. Gusella, I. Espinoza-Delgado, D. Longo, L. Varesio. 1994. Interferon-γ up-regulates interleukin-8 gene expression in human monocytic cells by a posttranscriptional mechanism. Blood 83: 537
    OpenUrlAbstract/FREE Full Text
  51. ↵
    Caput, D., B. Beutler, K. Hartog, R. Thayer, S. Brown-Shirmer, A. Cerami. 1986. Identification of a common nucleotide sequence in the 3′-untranslated region of mRNA molecules specifying inflammatory mediators. Proc. Natl. Acad. Sci. USA 83: 1670
    OpenUrlAbstract/FREE Full Text
  52. ↵
    Malter, J.. 1989. Identification of an AUUUA-specific messenger RNA binding protein. Science 246: 664
    OpenUrlAbstract/FREE Full Text
  53. ↵
    Crapper McLachlan, D. R., A. J. Dalton, T. P. Kruck, M. Y. Bell, W. L. Smith, W. Kalow, D. F. Andrews. 1991. Intramuscular desferrioxamine in patients with Alzheimer’s disease. Lancet 337: 1304
    OpenUrlCrossRefPubMed
  54. ↵
    Giardina, P., R. Grady. 1995. Chelation therapy in β-thalassemia: the benefits and limitation of desferrioxamine. Semin. Hematol. 32: 304
    OpenUrlPubMed
  55. ↵
    Blatt, J.. 1994. Desferoxamine in children with recurrent neuroblastoma. Anticancer Res. 14: 2109
    OpenUrlPubMed
  56. ↵
    Pfefferkorn, E. R.. 1984. Interferon γ blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan. Proc. Natl. Acad. Sci. USA 81: 908
    OpenUrlAbstract/FREE Full Text
  57. ↵
    Carlin, J. M., E. C. Borden, G. I. Byrne. 1999. Interferon-induced indoleamine 2,3-dioxygenase activity inhibits Clamydia psittaci replication in human macrophages. J. Interferon Res. 9: 329
    OpenUrl
  58. ↵
    Munn, D. H., E. Shafizadeh, J. T. Attwood, I. Bondarev, A. Pashine, A. L. Mellor. 1999. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med. 189: 1363
    OpenUrlAbstract/FREE Full Text
  59. ↵
    Alberati-Giani, D., P. Malherbe, P. Ricciardi-Castagnoli, C. Kohler, S. Denis-Donini, A. M. Cesura. 1997. Differential regulation of indoleamine 2,3-dioxygenase expression by nitric oxide and inflammatory mediators in IFN-γ-activated murine macrophages and microglial cells. J. Immunol. 159: 419
    OpenUrlAbstract
  60. ↵
    Heyes, M. P., K. Saito, D. Jacobowitz, S. P. Markey, O. Takikawa, J. H. Vickers. 1992. Poliovirus induces indoleamine 2,3-dioxygenase and quinolinic acid synthesis in macaque brain. FASEB J. 6: 2977
    OpenUrlAbstract
  61. ↵
    Taub, D., K. Conlon, A. Lloyd, J. Oppenheim, D. Kelvin. 1993. Preferential migration of activated CD4+ and CD8+ T cells in response to MIP-1α and MIP-1β. Science 260: 355
    OpenUrlAbstract/FREE Full Text
  62. ↵
    Cocchi, F., A. De Vico, A. Garzino-Demo, S. Arya, R. Gallo, P. Lusso. 1995. Identification of RANTES, MIP-1α and MIP-1β as the major HIV-suppressive factors produced by CD8+ T cells. Science 270: 1811
    OpenUrlAbstract/FREE Full Text
  63. ↵
    Alkhatib, G., C. Combadiere, C. C. Broder, Y. Feng, P. E. Kennedy, P. Murphy, E. A. Berger. 1996. CC CKR5: a RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272: 1955
    OpenUrlAbstract/FREE Full Text
  64. ↵
    Schmidtmayerova, H., S. L. H. Nottet, G. Nuovo, T. Raabe, C. R. Flanagan, L. Dubrovsky, H. E. Gendelman, A. Cerami, M. Bykrinsky, B. Sherry. 1996. Human immunodeficiency virus type 1 infection alters chemokine β peptide expression in human monocytes: implication for recruitment of leukocytes into brain and lymph nodes. Proc. Natl. Acad. Sci. USA 93: 700
    OpenUrlAbstract/FREE Full Text
  65. ↵
    Achim, C. L., M. P. Heyes, C. A. Wiley. 1993. Quantitation of human immunodeficiency virus, immune activation factors, and quinolinic acid in AIDS brain. J. Clin. Invest. 91: 2769
    OpenUrlCrossRefPubMed
Back to top

In this issue

The Journal of Immunology: 164 (6)
The Journal of Immunology
Vol. 164, Issue 6
15 Mar 2000
Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section